hijack
host
lipid
biosynthet
pathway
common
strategi
microbi
infect
human
envelop
virus
includ
hepat
c
viru
hcv
human
immunodefici
viru
hiv
use
cholesterolrich
lipid
raft
entri
assembl
andor
replic
lipid
droplet
ld
consid
static
storag
vesicl
host
lipid
appreci
dynam
organel
also
util
lifecycl
pathogen
human
virus
includ
rotaviru
rv
dengu
viru
dv
hcv
hcv
particular
requir
host
ld
assembl
nascent
viral
particl
hcv
global
import
human
pathogen
afflict
million
peopl
worldwid
hcv
hepaciviru
member
flavivirida
famili
envelop
viru
encod
singlestrand
positivesens
rna
genom
viral
rna
directli
translat
host
machineri
singl
polyprotein
cleav
host
virusencod
proteas
releas
individu
structur
core
nonstructur
ns
protein
infect
hcvencod
protein
promot
reorgan
accumul
ld
perinuclear
region
cell
hcv
core
protein
target
ld
orchestr
assembl
releas
infecti
viral
particl
late
stage
infect
henc
disrupt
interact
hcv
core
protein
ld
compromis
essenti
stage
within
hcv
lifecycl
sever
host
metabol
pathway
tightli
control
cellular
lipid
synthesi
target
disrupt
pathway
hcvencod
protein
link
liver
steatosi
hcvinfect
individu
importantli
correl
degre
steatosi
sever
chronic
hcv
infect
respons
treatment
ribavirin
overstimul
host
lipid
metabol
hcv
infect
achiev
varieti
molecular
mechan
review
exampl
hcv
employ
multipl
strategi
activ
sterol
regulatori
element
bind
protein
srebp
pathway
import
regul
host
lipid
homeostasi
srebp
endoplasm
reticulum
er
membraneanchor
transcript
factor
respond
chang
intracellular
sterol
level
interact
sterolsens
protein
review
sterol
level
high
srebp
retain
inact
precursor
er
low
sterol
condit
srebp
escort
golgi
two
resid
endoproteas
subtilisin
kexin
proteas
srebp
proteas
review
see
cleav
precursor
polypeptid
srebp
allow
releas
transcript
activ
srebp
molecul
er
releas
srebp
fragment
migrat
nucleu
bind
sterol
respons
element
promot
cholesterol
fatti
acid
biosynthet
target
gene
activ
transcript
activ
srebp
pathway
hcv
aid
viru
lifecycl
may
ultim
promot
develop
steatosi
liver
diseas
chronic
infect
individu
human
proteas
merop
also
wide
known
membranebound
subtilisinrel
serin
endoproteas
belong
group
nine
mammalian
proprotein
convertas
pc
famili
display
uniqu
substrat
specif
among
pc
member
show
prefer
cleavag
nonbas
amino
acid
cleav
carboxyterminu
peptidyl
sequenc
amino
acid
except
cy
posit
scissil
peptid
bond
hydrophob
amino
acid
contain
alkyl
side
chain
posit
addit
proteolyt
process
transcript
factor
particip
proteolyt
activ
viralenvelop
glycoprotein
lassa
viru
lymphocyt
choriomening
viru
crimean
congo
hemorrhag
fever
viru
importantli
endoproteolyt
process
viral
glycoprotein
critic
step
product
infecti
progeni
virus
suggest
may
repres
attract
target
therapeut
intervent
human
pathogen
arenavirus
given
proteolyt
cleavag
srebp
master
molecular
switch
control
host
cell
cholesterol
homeostasi
hypothes
inhibit
endoproteolyt
activ
secretori
pathway
would
prevent
hcv
hijack
host
lipid
metabol
pathway
thu
compromis
viru
lifecycl
previou
success
engin
serin
proteas
inhibitor
serpin
develop
effect
select
pc
inhibitor
hypothes
engin
natur
occur
serpin
scaffold
could
also
provid
power
approach
develop
select
inhibitor
serpin
differ
nonserpin
inhibitor
requir
larg
inhibitor
conform
chang
order
trap
proteas
irrevers
complex
conform
chang
initi
reaction
activ
serin
proteas
reactiv
center
loop
rcl
serpin
result
coval
speci
involv
acyl
ester
linkag
proteas
activ
site
serin
cleav
rcl
move
opposit
pole
serpin
take
tether
proteas
select
drosophila
serpin
prototyp
macromolecular
inhibitor
scaffold
identif
group
potent
natur
serpin
inhibitor
human
pc
furin
pm
provid
us
novel
uniqu
molecular
tool
dissect
contribut
proteolyt
activ
secretori
pathway
viral
infect
eukaryot
cell
report
engin
rcl
mimic
consensu
sequenc
cleavag
rcl
result
develop
novel
select
effect
serpinbas
inhibitor
demonstr
antiproteolyt
antihcv
activ
new
recombin
adenovirusexpress
secret
variant
direct
secretori
pathway
express
cell
result
strong
inhibit
activ
downregul
srebp
target
gene
product
hypothes
inhibit
activ
robustli
block
hcv
infect
cell
dosedepend
manner
found
specif
inhibit
activ
dramat
reduc
abund
ld
hepatoma
cell
use
specif
activ
sitedirect
smallmolecul
inhibitor
confirm
result
studi
proteinbas
therapeut
robust
inhibit
hcv
infect
result
studi
contribut
understand
hcv
lifecycl
hcvassoci
steatogenesi
effort
develop
novel
hostdirect
antivir
therapeut
agent
hcv
addit
find
increas
number
human
envelop
virus
employ
host
ld
infect
result
suggest
inhibitor
may
allow
develop
novel
broadspectrum
antivir
agent
previou
studi
demonstr
architectur
inhibit
two
evolutionari
diverg
member
pc
famili
furin
select
novel
drosophila
melanogast
serpin
scaffold
engin
novel
proteinbas
inhibitor
direct
pc
first
clone
prehisflagtag
construct
adenovir
shuttl
vector
gener
r
figur
uniqu
retain
r
serpin
present
cterminu
hdel
sequenc
figur
function
variant
ctermin
kdel
retent
signal
direct
secretori
protein
retent
er
cleavag
srebp
substrat
occur
golgi
apparatu
next
need
gener
secret
variant
figur
hypothes
variant
traffic
late
secretori
pathway
prior
secret
extracellular
space
would
encount
activ
molecul
earli
golgi
compart
accomplish
insert
stop
codon
ctermin
erretent
signal
hdel
next
employ
sitedirect
mutagenesi
optim
interact
rcl
substrat
bind
site
residu
posit
rcl
bait
region
substitut
gener
therebi
mimick
lassa
viru
glycoprotein
precursor
gpc
cleavag
site
figur
r
respect
test
serpinlik
properti
antivir
activ
variant
cellulo
recombin
adenovirus
ad
express
construct
r
produc
describ
previous
adenovirus
display
strong
tropism
liver
major
site
hcv
infect
recombin
adenovirus
especi
use
molecular
tool
hcv
research
includ
use
human
hepatoma
cell
support
robust
hcv
infect
cellulo
level
express
variant
first
optim
infect
human
hepatoma
cell
highli
permiss
hcv
infect
differ
multipl
infect
moi
recombin
adenoviru
express
intracellularli
retain
r
cellom
hc
analysi
reveal
cell
express
r
moi
figur
cellom
hc
also
use
determin
cell
death
occur
follow
day
pretreat
r
compar
control
adempti
follow
hour
hcv
infect
employ
experi
figur
observ
signific
reduct
total
cell
number
experiment
condit
highcont
analysi
cell
death
confirm
use
mtsbase
cell
viabil
assay
data
shown
lack
detect
toxic
induc
r
moi
show
variant
test
wide
dynam
rang
hepatoma
cell
serpinsecret
profil
cell
examin
western
blot
cell
lysat
extracellular
media
expect
promin
band
detect
r
infect
infect
cell
lysat
use
antiflag
antibodi
figur
lane
furthermor
hypothes
band
r
found
lyse
cell
extract
found
secret
extracellular
media
figur
lane
convers
band
detect
whole
cell
extract
cell
media
figur
lane
result
confirm
robust
intracellular
express
intact
flagtag
recombin
serpin
protein
band
differenti
secret
r
cell
stabl
acylenzym
complex
form
proteas
function
inhibitori
serpin
follow
rcl
cleavag
allow
detect
high
molecular
weight
heatstabl
sdsstabl
enzymeinhibitor
ei
complex
standard
sdspage
western
blot
determin
function
select
inhibitor
recombin
variant
furin
inhibitor
express
cell
hour
cell
media
extract
contain
recombin
serpin
harvest
incub
purifi
recombin
histag
human
furin
figur
describ
previous
reaction
mixtur
analyz
western
blot
probe
ei
complex
format
antihi
antibodi
figur
antiflag
antibodi
figur
result
shown
figur
clearli
demonstr
ei
complex
format
recombin
cell
media
cell
extract
lane
upper
lower
panel
expect
form
complex
furin
figur
lane
upper
lower
panel
wherea
furindirect
serpin
form
ei
complex
furin
cell
media
extract
figur
lane
respect
upper
lower
panel
lyse
cellular
extract
express
r
also
demonstr
ei
complex
format
figur
lane
bottom
panel
result
biochem
analysi
confirm
serpinlik
properti
recombin
r
biosynthes
human
hepatoma
cell
select
importantli
inhibit
suicid
substrat
mechan
form
kinet
trap
heat
sdsstabl
complex
characterist
physiolog
serpinproteas
pair
confirm
express
cell
inhibit
endogen
cleavag
srebp
molecul
examin
nuclear
protein
level
cell
infect
adenovirusexpress
variant
posit
control
also
treat
cell
select
revers
competit
smallmolecul
inhibitor
compound
recent
synthes
character
vitro
vivo
antilipidem
properti
includ
effici
inhibit
nuclear
srebp
accumul
previous
describ
calpain
inhibitor
alphanacetylleuleunlecho
alln
employ
facilit
detect
accumul
ntermin
fragment
nucleu
antifibrillarin
antibodi
use
posit
identifi
nuclear
fraction
figur
expect
western
blot
nuclear
extract
cell
treat
alln
use
antibodi
ntermin
fragment
reveal
complet
block
accumul
nucleu
figur
nuclear
extract
cell
infect
rrll
alln
also
exhibit
dramat
decreas
nuclear
accumul
compar
adempti
control
alln
r
rrll
r
alln
infect
cell
result
confirm
express
recombin
secretori
pathway
cell
inhibit
process
next
determin
whether
mediat
reduct
nuclear
srebp
associ
concomit
decreas
protein
level
srebptarget
gene
examin
fate
three
srebpdepend
gene
product
ldlr
investig
host
cell
protein
propos
contribut
hcv
entri
ldlr
propag
time
cours
analysi
cell
express
complet
media
show
signific
block
srebpregul
ldlr
express
hour
figur
hcv
known
induc
srebp
activ
analyz
express
srebpregul
protein
srebpactiv
condit
figur
cell
deplet
exogen
sterol
hour
induc
srebp
transport
ertogolgi
prior
infect
adempti
r
level
ldlr
regul
nuclear
srebp
measur
use
western
blot
analysi
lyse
cell
extract
figur
hour
express
matur
ldlr
kda
level
reduc
compar
ademptytr
cell
similarli
block
matur
kda
express
reduct
fulllength
express
observ
signific
reduct
ldlr
level
follow
r
treatment
observ
interestingli
signific
reduct
express
detect
r
express
cell
figur
express
golgi
marker
affect
r
express
figur
result
confirm
express
cell
specif
inhibit
srebp
pathway
includ
target
gene
identifi
cellular
cofactor
affect
hcv
infect
critic
function
srebp
pathway
gene
regul
control
lipid
homeostasi
investig
impact
inhibit
use
total
intracellular
lipid
level
specif
cholesterol
cholesterolest
triglycerid
phospholipid
figur
among
cell
lipid
examin
dramat
impact
cholesterolest
level
major
constitu
cellular
ld
reduc
treat
cell
compar
control
adempti
treat
cell
figur
similarli
reduc
cholesterolest
level
compar
control
cell
treat
dmso
figur
reduct
triglycerid
also
induc
although
reduct
reach
signific
wherea
caus
signific
reduct
total
intracellular
triglycerid
signific
reduct
free
cholesterol
level
also
observ
treat
cell
reduct
observ
cell
compar
respect
control
signific
reduct
phospholipid
level
detect
figur
result
suggest
sustain
inhibit
cleavag
activ
srebp
caus
increas
cellular
util
lipid
store
ld
dynam
intracellular
lipid
storag
compart
made
triglycerid
cholesterol
ester
surround
phospholipid
membran
associ
specif
marker
protein
includ
adipos
differentiationrel
protein
adrp
also
known
perlipin
srebp
activ
control
express
gene
directli
involv
intracellular
fatti
acid
cholesterol
biosynthesi
review
cholesterolest
level
reduc
investig
effect
serpinmedi
inhibit
cellular
ld
abund
fluoresc
microscopi
use
determin
rel
abund
ld
stain
bodipi
cell
infect
adempti
control
r
hour
level
bodipystain
ld
express
cell
dramat
reduc
compar
empti
vectortr
cell
figur
contrast
r
express
cell
appar
reduct
ld
size
abund
compar
controltr
cell
figur
quantif
confoc
microscopi
imag
demonstr
averag
ld
abund
reduc
express
cell
compar
control
figur
effect
express
cytosol
ld
abund
confirm
visual
ld
marker
adrpperilipin
use
confoc
microscopi
figur
use
quantit
western
blot
figur
observ
reduc
adrpperilipin
protein
express
compar
control
cell
figur
wherea
reduct
adrpperlipin
express
follow
r
treatment
subsequ
confirm
reduc
cellular
ld
level
due
inhibit
use
whereupon
adrpperilipin
level
reduc
compar
control
dmsotreat
cell
figur
result
confirm
inhibit
enzymat
activ
dramat
reduc
intracellular
ld
abund
cell
sinc
srebp
signal
pathway
induc
hcvencod
protein
infect
test
effect
inhibit
pathway
hcv
lifecycl
human
hepatoma
cell
cell
treat
increas
moi
r
adempti
control
hour
complet
media
without
exogen
ad
sterol
follow
hour
infect
hcv
number
hcvinfect
cell
evidenc
posit
core
protein
express
measur
use
cellom
hc
figur
determin
express
inhibit
hcv
infect
dosedepend
manner
compar
controltr
cell
hcv
infect
significantli
reduc
cell
infect
moi
moi
howev
caus
reduct
moi
caus
reduct
moi
caus
reduct
number
hcvinfect
cell
compar
control
r
signific
impact
hcv
infect
adenoviru
moi
compar
control
figur
supplement
sterol
lipid
metabolit
significantli
restor
infect
cell
treat
moi
increas
hcv
infect
compar
nonsuppl
cell
observ
figur
result
show
antihcv
activ
least
part
associ
capac
decreas
intracellular
lipid
store
within
host
cell
antihcv
properti
confirm
extend
virolog
studi
cell
pretreat
serpinbas
inhibitor
hour
prior
hour
hcv
infect
figur
first
quantit
western
blot
analysi
reveal
reduct
express
intracellular
hcv
core
protein
express
cell
compar
control
figur
similarli
treatment
found
reduc
extracellular
infecti
hcv
titer
figur
reduct
intracellular
hcv
rna
level
also
observ
use
quantit
pcr
qpcr
analysi
figur
r
express
significantli
impact
aspect
hcv
lifecycl
examin
figur
result
demonstr
inhibit
proteolyt
activ
srebp
molecul
use
secretori
pathway
proteinbas
inhibitor
effect
antivir
strategi
robustli
block
hcv
infect
cell
determin
decreas
intracellular
hcv
rna
treat
cell
figur
due
reduc
viral
replic
altern
due
reduc
hcv
entri
examin
cell
transfect
directli
total
genom
hcv
rna
day
follow
hour
adenovirusmedi
serpin
express
found
experiment
condit
receptormedi
hcv
entri
bypass
signific
chang
intracellular
hcv
rna
level
detect
qpcr
figur
examin
total
cell
extract
western
blot
reveal
hcv
core
level
reduc
follow
hcv
rna
transfect
serpintr
cell
figur
confirm
interfer
hcv
replic
hcv
entri
bypass
impact
treatment
hcv
replic
investig
use
hcv
subgenom
replicon
human
hepatoma
cell
harbour
stabl
hcv
replicon
encod
wildtyp
cell
adapt
mutat
cell
treat
recombin
adenovirus
day
total
rna
level
harvest
level
hcv
rna
quantifi
use
qpcr
analysi
signific
differ
observ
hcv
replicon
level
treat
r
control
adempti
figur
result
confirm
inhibit
hcv
replic
find
addit
measur
decreas
ldlr
express
present
figur
strongli
suggest
robust
reduct
intracellular
hcv
rna
level
observ
pretreat
cell
prior
hcv
infect
least
part
due
reduc
viral
attach
entri
next
want
test
whether
extracellularli
appli
would
effect
inhibit
endoproteolyt
activ
secretori
pathway
reduc
hcv
infect
cell
first
use
mtsbase
cell
viabil
assay
confirm
major
cytotox
effect
occur
cell
treat
figur
next
cell
treat
increas
concentr
hour
cell
media
replac
cell
infect
hour
hcv
number
hcvinfect
cell
indic
posit
core
protein
express
measur
use
cellom
hc
figur
left
panel
expect
host
cell
pretreat
result
dosedepend
decreas
number
hcvinfect
cell
figur
right
panel
near
complet
block
hcv
infect
observ
follow
treatment
inhibitor
figur
right
panel
examin
impact
prophylact
treatment
differ
stage
hcv
lifecycl
next
test
effect
pretreat
product
infecti
progeni
virion
normal
detect
hour
posthcv
infect
cell
experiment
condit
reduct
extracellular
viral
titer
observ
figur
left
panel
concentr
interestingli
singl
prophylact
pretreat
cell
suffici
maintain
decreas
intracellular
hcv
core
product
hour
postinfect
valu
figur
right
panel
result
indic
pretreat
host
cell
suffici
robustli
block
hcv
infect
prevent
hcv
entri
andor
downstream
product
infecti
progeni
virion
elucid
lifecycl
stage
compromis
treatment
test
effect
compound
ad
hcv
entri
stage
cell
hypothes
entri
stage
hcv
lifecycl
block
srebp
cleavag
inhibit
addit
hour
posthcv
infect
impact
progress
hcv
infect
test
hypothesi
cell
first
infect
hcv
hour
allow
uninterrupt
hcv
entri
establish
infect
hcvcontain
media
remov
cell
treat
scenario
hcv
infect
reduc
cell
treat
compar
dmsotreat
cell
figur
right
panel
infecti
viru
product
extracellular
viral
titer
reduc
follow
treatment
inhibitor
figur
right
panel
result
indic
inhibit
also
inhibit
postentri
stage
hcv
lifecycl
decreas
abund
ld
compon
hypothes
hcv
assembl
rather
hcv
replic
also
block
inhibit
support
hypothesi
cell
treat
hour
signific
chang
hcv
subgenom
rna
level
either
cell
line
figur
treat
observ
compar
dmsotreat
control
summari
lack
effect
hcv
replicon
level
compar
two
set
data
present
figur
demonstr
strong
antivir
effect
ad
either
pre
posthcv
inocul
propos
pharmacolog
inhibit
endoproteolyt
activ
impact
late
assembl
stage
hcv
lifecycl
investig
biolog
consequ
inhibit
endoproteas
activ
biochem
pathway
lipid
homeostasi
hijack
hcv
first
employ
proteinbas
inhibitor
strategi
engin
develop
novel
recombin
adenoviru
express
effect
specif
secretori
pathway
serpin
show
form
kinet
trap
heat
sdsstabl
complex
molecul
characterist
physiolog
serpinproteas
pair
demonstr
block
cleavag
endogen
express
srebp
downstream
effector
gene
product
eg
ldlr
srebp
target
gene
product
identifi
treat
cell
involv
lipid
homeostasi
report
particip
hcvhost
interact
along
srebp
isoform
activ
hcvencod
protein
hcv
infect
implic
hcv
infect
regul
two
hcv
entri
factor
ldlr
although
specif
role
ldlr
hcv
infect
unclear
increas
evid
indic
ldlr
promot
attach
uptak
lipoproteinassoci
hcv
particl
hepatocyt
addit
block
srebpmedi
upregul
hepat
gene
hcv
infect
hypothes
block
endoproteas
activ
would
also
compromis
cellular
lipid
storag
analysi
intracellular
lipid
content
cytoplasm
ld
abund
express
cell
confirm
hypothesi
addit
observ
decreas
adrpperilipin
abund
express
cell
compar
controltr
cell
physiolog
role
adrp
yet
fulli
establish
play
import
role
ld
structur
format
interestingli
adrp
degrad
proteasomedepend
pathway
regress
lipidstor
cell
indic
adrp
bound
ld
cell
suscept
rapid
proteasom
degrad
clinic
studi
demonstr
correl
level
adrp
degre
hepatocyt
steatogenesi
human
addit
adrp
found
upregul
fatti
liver
human
mice
liver
steatosi
collect
observ
suggest
inhibit
offer
attract
therapeut
target
reduc
hcvinduc
liver
steatosi
hypothes
inhibit
srebp
endoproteolyt
cleavag
event
use
result
dosedepend
decreas
hcv
infect
demonstr
hcv
core
express
hcv
rna
level
reduc
express
cell
follow
hcv
infect
lead
robust
reduct
extracellular
infecti
hcv
particl
releas
western
blot
also
confirm
hcv
core
protein
posttransl
process
unalt
serpin
express
size
protein
unalt
supplement
express
cell
compound
mevalon
oleat
cholesterol
result
incomplet
rescu
hcv
infect
suggest
antivir
activ
proteinbas
inhibitor
explain
sole
decreas
avail
lipid
cell
also
support
hypothesi
reduc
ldlr
level
may
compromis
hcv
entri
treat
hepatocyt
ldlr
wellestablish
srebpregul
gene
repeatedli
shown
support
hcv
entri
hepatocyt
also
signific
reduct
hcv
rna
level
observ
treat
cell
harbour
subgenom
hcv
replicon
follow
fulllength
genom
hcv
rna
transfect
cell
altogeth
studi
indic
observ
declin
hcv
rna
level
follow
hcv
infect
may
result
compromis
hcv
entri
gain
insight
differ
stage
viral
lifecycl
target
inhibitor
use
activesitedirect
smallmolecul
inhibitor
pharmacolog
inhibitor
recent
character
effect
block
cleavag
block
express
srebpactiv
gene
also
inhibit
arenaviru
glycoprotein
process
contrast
recombin
adenovirusexpress
serpin
ad
extracellularli
rapidli
inhibit
allow
us
studi
biolog
impact
block
pathway
earli
late
stage
hcv
infect
first
confirm
reduct
abund
neutral
lipid
adrpperilipin
express
cell
confirm
inhibit
use
block
hcv
infect
extracellular
infecti
viru
product
dosedepend
manner
antihcv
activ
robust
particularli
strike
singl
pretreat
compound
suffici
block
hcv
infect
antivir
effect
still
appar
hour
posttreat
importantli
pharmacolog
treatment
alreadi
infect
hcv
cell
result
reduct
hcv
viru
product
similar
treatment
reduc
hcv
rna
level
two
stabl
subgenom
replicon
cell
line
examin
combin
observ
reduct
abund
central
organel
ld
involv
hcv
assembl
reduct
hcv
particl
secret
cell
treat
hour
hcv
inocul
support
inhibitor
late
stage
hcv
lifecycl
ie
assembl
egress
taken
togeth
result
indic
inhibit
interrupt
hcv
lifecycl
multipl
stage
viral
infect
prevent
cell
becom
infect
prevent
viru
releas
alreadi
infect
cell
popul
thu
develop
effect
activesitedirect
smallmolecul
inhibitor
nm
rang
better
pharmacokinet
properti
could
lead
novel
indirectact
antivir
treatment
option
hcvinfect
patient
importantli
inhibit
srebp
pathway
hcvinfect
cell
exacerb
lipid
product
steatot
may
reliev
symptom
caus
chronic
hcv
infect
addit
block
viral
infect
conclus
pharmacolog
inhibit
offer
promis
avenu
develop
novel
antihcv
therapeut
figur
one
hand
target
host
cell
master
molecular
switch
novel
class
drug
compromis
multipl
stage
viru
lifecycl
would
main
advantag
make
difficult
viru
develop
escap
mutat
hand
toxic
issu
associ
inhibit
host
cell
proteas
could
address
use
adjunct
therapi
combin
novel
class
lipidmodul
agent
current
standard
care
appropri
synergist
directact
antivir
final
result
reveal
target
host
ld
biogenesi
inhibit
endoproteolyt
activ
may
farreach
applic
therapeut
treatment
import
human
flavivirida
virus
dengu
viru
whose
replic
pathogenesi
also
depend
interact
lipid
droplet
human
hepatoma
cell
kindli
provid
dr
franci
chisari
scripp
research
institut
la
jolla
ca
usa
cell
support
hcv
genotyp
subgenom
replicon
cell
support
replicon
adapt
mutat
provid
dr
charl
rice
rockefel
univers
new
york
ny
apath
llc
st
loui
mo
usa
cultur
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
penicillin
streptomycin
glutamin
nonessenti
amino
acid
acid
hepe
fetal
bovin
serum
fb
gibcoinvitrogen
burlington
canada
lipoproteindeplet
serum
lpd
biomed
technolog
inc
stoughton
usa
also
maintain
select
geneticin
invitrogen
bovin
serum
albumin
bsa
saponin
cholesterol
acid
lacton
oleaic
acid
obtain
sigmaaldrich
corp
st
loui
mo
usa
formaldehyd
wv
obtain
fischer
scientif
pittsburgh
pa
usa
mous
anticor
antibodi
abcam
cambridg
usa
employ
detect
hcv
infect
antibodi
use
detect
cellular
protein
includ
rabbit
antihuman
proprotein
convertas
subtilisinkexin
type
abcam
rabbit
antildlr
fitzgerald
industri
intern
inc
concord
usa
mous
santa
cruz
biotechnolog
santa
cruz
ca
usa
rabbit
antiadipos
differentiationrel
protein
adrp
abcam
mous
antiadrp
progen
heidelberg
germani
rabbit
abcam
mous
lab
vision
corpor
qc
canada
mous
bd
bioscienc
mississauga
canada
rabbit
clone
santa
cruz
biotechnolog
mous
antifibrillarin
abcam
tag
protein
detect
use
mous
antiflag
western
blot
immunofluoresc
sigmaaldrich
corp
rabbit
antiflag
western
blot
immunofluoresc
thermo
scientif
nepean
canada
mous
antihi
antibodi
appli
biolog
materi
richmond
bc
canada
secondari
antibodi
use
immunofluoresc
alexa
alexa
donkey
antimous
donkey
antirabbit
antibodi
molecular
probesinvitrogen
secondari
antibodi
use
western
blot
irdy
red
band
green
band
donkey
antimous
goat
antirabbit
antibodi
licor
bioscienc
lincoln
ne
usa
hoechst
bodipi
molecular
probesinvitrogen
use
detect
nuclei
ld
respect
plasmid
contain
cdna
hcv
consensu
clone
isol
japanes
patient
fulmin
hepat
genbank
access
number
clone
behind
promot
gener
gift
dr
takaji
wakita
nation
institut
infecti
diseas
tokyo
japan
use
gener
genom
hcv
rna
infecti
hcv
stock
previous
describ
purifi
hcv
rna
use
transfect
cell
mean
studi
hcv
infect
independ
receptormedi
entri
five
microgram
purifi
rna
incub
lipofectamin
invitrogen
minim
essenti
media
mem
minut
rnalipid
complex
ad
cell
mem
hour
cell
wash
phosphatebuff
salin
pb
complet
media
ad
remaind
experi
amount
infecti
hcv
particl
gener
viral
stock
describ
experi
determin
use
modifi
previous
describ
protocol
briefli
cell
plate
well
plate
infect
serial
dilut
hcvinfect
cell
media
hour
postinfect
cell
fix
probe
describ
arrayscan
quantif
method
section
arrayscan
vti
high
content
screen
hc
reader
thermo
scientif
use
acquir
imag
entir
group
infect
well
titer
determin
manual
count
foci
fluoresc
form
unit
ffu
lowest
dilut
posit
signal
genbank
access
number
potent
effect
natur
serpin
pc
identifi
date
reason
select
prototyp
protein
inhibitor
scaffold
engin
secretori
pathway
inhibitor
first
nterminu
modifi
encod
signal
peptid
residu
follow
tag
hhhhhh
flagtag
dykddddk
sequenc
hf
direct
furin
contain
cleavag
sequenc
rrkr
reactiv
center
loop
rcl
er
retain
r
variant
furindirect
serpin
design
r
figur
present
hisaspgluleu
hdel
er
retent
motif
cterminu
secret
variant
serpin
gener
mutat
codon
hdel
sequenc
stop
codon
report
cleav
lassa
viru
glycoprotein
sequenc
rrll
thu
specif
target
enzym
alter
furindirect
rcl
sequenc
rrll
sitedirect
mutagenesi
use
quikchang
stratagen
la
jolla
ca
usa
gener
r
figur
produc
r
construct
clone
adenoviru
vector
pshuttl
amplifi
viraquest
inc
north
liberti
ia
usa
adenoviru
titer
determin
human
embryon
kidney
cell
use
adenox
rapid
titer
kit
clontech
mountain
view
ca
usa
empti
adenoviru
adempti
kindli
provid
dr
jan
breslow
rockefel
univers
new
york
ny
usa
amplifi
viraquest
inc
drosophila
melanogast
sequenc
genebank
access
number
exhibit
sequenc
homolog
human
neuroserpin
hn
crystal
structur
avail
protein
data
bank
pdb
id
five
chain
pentamer
structur
hn
chain
b
well
resolv
fewest
miss
residu
use
templat
homolog
model
present
figur
model
built
refin
use
swisspdb
viewer
calpha
residu
model
structur
align
rmsd
refer
hn
structur
first
amino
acid
human
lack
ctermin
transmembran
domain
contain
ctermin
pgddddkhhhhhhhhsg
express
insect
cell
previous
describ
two
liter
cell
cultur
supernat
use
purif
two
hundr
millilit
mm
trishcl
ph
mm
nacl
ad
ph
adjust
ph
addit
naoh
result
precipit
remov
centrifug
x
g
minut
subsequ
filter
glass
filter
clear
supernat
appli
small
ml
column
volum
imac
column
nisepharos
ge
healthcar
freiburg
germani
continu
flow
mlminut
column
previous
equilibr
mm
trishcl
ph
mm
nacl
buffer
bound
recombin
elut
continu
gradient
column
volum
buffer
plu
mm
imidazol
collect
fraction
assay
enzymat
activ
previous
describ
use
paranitroanilid
pna
acetyl
ac
tetrapeptidyl
substrat
acrrllpna
custom
synthes
peptid
intern
louisvil
kentucki
usa
activ
fraction
pool
concentr
buffer
exchang
buffer
done
use
spin
concentr
millipor
billerica
usa
molecular
weight
cutoff
kda
final
prepar
addit
vv
glycerol
store
specif
activ
umg
measur
recombin
histag
furin
mgml
purchas
r
system
minneapoli
mn
usa
reaction
adenoviru
recombin
serpin
perform
buffer
condit
furin
assay
previous
describ
cultur
cell
wash
icecold
pb
resuspend
cold
radioimmunoprecipit
assay
ripa
buffer
mm
trishcl
ph
mm
nacl
octylphenylpolyethylen
glycol
igep
sodium
deoxychol
sodium
dodecyl
sulfat
sd
contain
x
complet
edtafre
proteas
inhibitor
cocktail
roch
laval
qc
canada
whole
cell
extract
vortex
clarifi
centrifug
x
g
minut
solubl
extract
mix
x
sampl
buffer
mm
trishcl
ph
glycerol
sd
bromophenol
blue
betamercaptoethanol
electrophores
sd
polyacrylamid
gel
transfer
nitrocellulos
membran
membran
block
odyssey
block
buffer
licor
bioscienc
one
hour
protein
interest
detect
probe
appropri
primari
secondari
antibodi
dilut
odyssey
block
buffer
contain
tween
protein
band
detect
quantifi
use
odyssey
infrar
imag
system
licor
bioscienc
immunoblot
scan
wavelength
nm
detect
irdy
label
antibodi
wavelength
nm
irdy
conjug
antibodi
signal
intens
quantifi
mean
odyssey
softwar
version
betatubulin
alway
use
load
control
normal
protein
express
media
sampl
analyz
secret
variant
taken
directli
cultur
cell
mix
x
sampl
load
buffer
subject
describ
western
blot
analysi
cell
plate
cell
per
well
plate
infect
hour
r
adempti
moi
hour
media
cell
extract
harvest
hypoton
buffer
contain
mm
tri
ph
mm
mm
mix
enzym
reaction
buffer
buffer
contain
mm
trishcl
mm
me
ph
mm
furin
buffer
contain
mm
hepe
ph
mm
triton
x
complet
edtafre
proteas
inhibitor
cocktail
furin
enzym
mixtur
incub
minut
reaction
stop
mm
edta
final
concentr
complet
product
resolv
sdsgel
highmolecular
weight
band
ei
visual
describ
western
blot
black
flatbottom
plate
bd
bioscienc
cell
plate
cellswel
infect
describ
method
follow
infect
cell
fix
formaldehyd
vv
dilut
pb
block
pb
contain
bsa
triton
fb
cell
first
probe
hcv
anticor
antibodi
pb
contain
bsa
triton
bind
buffer
incub
alexa
donkey
antimous
secondari
antibodi
hoechst
dye
cell
analyz
quantit
highthroughput
fluoresc
microscop
system
call
cellom
arrayscan
vti
high
content
screen
hc
reader
thermo
scientif
use
softwar
target
activ
bioapplic
taba
taba
use
count
total
number
cell
hoechststain
nuclei
percentag
cell
express
hcv
core
posit
signal
nm
wavelength
day
cell
plate
mm
plate
day
cell
infect
recombin
adenovirus
express
r
ad
empti
moi
day
separ
cell
treat
inhibitor
control
dmso
day
sampl
except
untreat
control
treat
hour
amino
pentanamid
sigmaaldrich
corp
nuclear
fraction
cell
lysat
perform
describ
previous
modif
cell
harvest
buffer
c
mm
hepeskoh
ph
mm
kcl
mm
mm
edta
mm
egta
mm
sucros
contain
x
complet
proteas
inhibitor
cocktail
roch
shear
dna
cell
pass
time
needl
lysat
centrifug
x
g
minut
result
supernat
centrifug
x
g
minut
obtain
membran
pellet
pellet
contain
membranebound
resuspend
sdslysi
buffer
mm
tri
hcl
mm
nacl
sd
mm
edta
mm
egta
ph
pellet
x
g
spin
resuspend
buffer
mm
hepeskoh
mm
nacl
mm
glycerol
mm
edta
mm
egta
ph
contain
x
complet
proteas
inhibitor
cocktail
nuclear
pellet
rock
hour
sampl
centrifug
x
g
minut
obtain
clarifi
supernat
contain
nuclear
fraction
cell
seed
onto
coverslip
hour
infect
adenoviru
moi
hour
cell
fix
vv
formaldehyd
pb
permeabil
block
pb
contain
saponin
wash
buffer
bsa
bind
buffer
block
cell
stain
bodipi
done
presenc
glycin
reduc
background
fluoresc
cell
probe
primari
antibodi
bind
buffer
incub
secondari
antibodi
hoechst
dye
bodipi
indic
dilut
pb
cell
mount
onto
slide
antifad
solut
seal
clear
nail
polish
slide
imag
use
leica
tc
confoc
microscop
leica
microsystem
wetzlar
germani
olympu
fluoview
laser
scan
confoc
microscop
olympu
corpor
tokyo
japan
leica
mm
af
softwar
leica
microsystem
use
count
number
ld
green
channel
cell
express
r
n
n
cell
posit
red
channel
ld
cell
treat
adempti
n
also
enumer
quantifi
imag
acquir
use
laser
intens
gain
set
ld
enumer
appli
threshold
set
imag
cell
infect
recombin
adenoviru
differ
moi
complet
media
without
exogen
sterol
sodium
mevalon
sodium
oleat
cholesterol
hour
cell
infect
hcv
moi
transfect
purifi
hcv
genom
rna
hour
cell
analyz
cellom
arrayscan
hc
total
rna
isol
cell
extract
use
rneasi
plu
kit
qiagen
mississauga
canada
includ
oncolumn
dnase
digest
media
treat
infect
cell
harvest
hcv
titer
determin
describ
examin
mediat
block
ldlr
express
cell
grown
media
supplement
lpd
hour
infect
adenoviru
variant
harvest
hour
later
purifi
total
rna
revers
transcrib
cdna
use
taqman
revers
transcript
reagent
random
hexam
appli
biosystem
foster
citi
ca
usa
realtim
quantit
pcr
carri
use
brilliant
ii
fast
qpcr
reagent
stratagen
la
jolla
ca
usa
accord
manufactur
instruct
qpcr
system
stratagen
onlin
probefind
softwar
roch
appli
scienc
use
find
primer
would
allow
amplif
hcv
rna
end
combin
human
univers
probe
librari
roch
roch
appli
scienc
amplif
hcv
rna
region
nm
forward
primer
revers
primer
use
combin
nm
probe
human
probe
librari
roch
hcv
rna
level
rel
quantifi
across
sampl
normal
betaactin
rna
level
use
nm
primer
forward
gcc
ctg
agg
cac
tct
tcc
revers
gga
tgt
cca
cgt
cac
act
nm
probe
tcc
atg
ccc
agg
aag
gaa
fluorophor
black
hole
quencher
cell
viabil
determin
use
celltit
aqueou
one
solut
cell
prolifer
assay
promega
madison
wi
usa
assay
employ
tetrazolium
compound
inner
salt
mt
bioreduc
cell
color
formazan
product
detect
tissu
cultur
media
nm
wavelength
activ
sitedirect
smallmolecul
inhibitor
synthes
dr
peter
chua
center
drug
research
develop
cdrd
univers
british
columbia
vancouv
bc
canada
accord
previous
describ
protocol
investig
antivir
activ
small
molecul
cell
treat
hour
hour
treatment
media
remov
cell
infect
hcv
moi
hour
altern
cell
first
infect
hcv
hour
media
remov
replac
media
contain
variou
concentr
hour
intracellular
hcv
infect
level
determin
use
cellom
hc
arrayscan
infecti
extracellular
titer
determin
media
hcvinfect
cell
measur
level
intracellular
lipid
follow
recombin
adenoviru
express
treatment
cellular
extract
harvest
tritonx
pb
phospholipid
cholesterol
protein
assay
tritonx
triglycerid
assay
extract
triglycerid
sampl
slowli
heat
brought
room
temperatur
twice
total
cholesterol
cholesterol
ester
amplex
red
cholesterol
assay
kit
invitrogen
phospholipid
triglycerid
enzchrom
bioassay
system
hayward
ca
usa
quantifi
use
commerci
avail
kit
lipid
level
normal
cellular
protein
content
dc
protein
assay
biorad
hercul
ca
usa
sigmoid
fit
function
igor
pro
softwar
wavemetr
inc
portland
usa
use
fit
hcv
inhibit
curv
determin
valu
report
valu
averag
valu
calcul
three
independ
experi
plu
minu
standard
deviat
student
ttest
unpair
use
calcul
signific
repres
figur
follow
notat
denot
p
denot
p
denot
p
